- EB-105 is the world's first pentavalent trispecific antibody
targeting VEGF-A, VEGF-B, PlGF, Ang-2 and IL-6R in DME
- LOTUS study is the initial clinical trial of Eluminex's
EB-105 being conducted in the United
States
SAN
FRANCISCO and SUZHOU, China, July 15,
2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex),
a clinical stage, privately held biotechnology company focused on
the development of advanced protein therapeutics for
vision-threatening diseases announced the first dosing of EB-105 in
patients with DME. The LOTUS trial is a first-in-human,
open-label, multicenter, single injection, dose-escalation
study of EB-105, Eluminex's lead ophthalmology asset being
conducted at four sites in the United
States. EB-105 has been shown in preclinical studies to
potently inhibit VEGF-A/VEGFR-2, Ang-2/Tie-2, and IL-6/IL-6R
signaling. Vitreous levels of IL-6, an inflammatory cytokine
known to play a role in endothelial cell barrier dysfunction
leading to vascular leakage, are elevated in patients with retinal
disease including DME, diabetic retinopathy, neovascular (wet)
age-related macular degeneration, and retinal vein occlusion.
Dr. Ashkan Abbey, MD, Director of
Clinical Research at Texas Retina Associates was the first retinal
surgeon in the world to administer EB-105 treatment in the clinic.
"Retina specialists welcome the addition of IL-6 pathway
inhibition. We are in need of newer agents for these often
difficult to manage patients. It is our hope that EB-105 will
translate into incremental improvements in visual acuity,
durability of response, and improved drying of the retina," he
commented. "EB-105 represents a significant advance in the rapidly
emerging science of polyvalent protein engineering," stated
Charles Semba, MD, Eluminex's Chief Medical Officer. "For
patients, it offers the promise of broader coverage of known
biologic pathways associated with diabetic retinopathy and
potentially better outcomes beyond currently available therapies,"
he added.
About the LOTUS Trial
LOTUS is a multicenter, single intravitreal (IVT) injection dose
escalation study that will evaluate three dose levels of EB-105 in
patients with center-involved diabetic macular edema and will
enroll approximately 12 patients (4 per dose level). The primary
objectives are safety, tolerability and pharmacodynamics (as
assessed by imaging and visual acuity assessments) and to select
the two best doses for a separate repeat injection study that is
anticipated in 2025. Topline data from the current single injection
study is anticipated in 1H 2025. In addition to Dr. Abbey are the
following leading retinal surgeon investigators: Carl Awh, MD, Tennessee Retina, Nashville, TN; Veeral
Sheth, MD, University Retina, Lemont, IL, and Charles Wyckoff, MD, Retina Consultants of
Houston, Houston, TX. The study is being facilitated by
the clinical research organization (CRO) Vial, Inc., based in
San Francisco, CA.
About Eluminex Biosciences
Eluminex was founded in early 2020. The company headquarters,
research and development (R&D) center, and Good Manufacturing
Practices (GMP) manufacturing facilities are located in Suzhou
Industrial Park BioBAY, China, and
the US regional office is located in Mountain View, California. Eluminex is
currently supported by leading venture groups including Lilly Asia
Ventures, Quan Capital, Hillhouse BioVenture, Cenova Capital, and
3E BioVentures and has raised over $100M (USD) through Series B+ financing. For more
information: www.eluminexbio.com.
View original
content:https://www.prnewswire.com/news-releases/eluminex-biosciences-announces-first-patient-dosed-in-the-phase-1b-lotus-trial-of-the-novel-trispecific-fusion-antibody-eb-105-in-diabetic-macular-edema-dme-302196410.html
SOURCE Eluminex Biosciences